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A B S T R A C T
The aim of this study was to develop an intravenous clarithromycin lipid emulsion (CLE)
with good stability and excellent antibacterial activity. The CLE was prepared by the thin-
film dispersed homogenization method. The interaction between clarithromycin (CLA) and
cholesteryl hemisuccinate (CHEMS) was confirmed by DSC, FT-IR and 1H NMR analysis. The
interfacial drug loading, thermal sterilization, freeze–thaw stability, and in vitro and in vivo
antibacterial activity were investigated systematically. DSC, FT-IR and 1H NMR spectra showed
that CHEMS (CLA: CHEMS, M ratio 1:2) could interact with CLA through H-bonding and a
hydrogen-bonded ion pair. The CHEMS was found necessary to maintain the stability of CLE.
Ultracentrifugation showed that almost 88% CLA could be loaded into the interfacial layer.
The optimized CLE formulation could withstand autoclaving at 121 °C for 10 min and remain
stable after three freeze–thaw cycles. The in vitro susceptibility test revealed that the CLA–
CHEMS ion-pair and CLE have similar activity to the parent drug against many different
bacterial strains. The in vivo antibacterial activity showed that the ED50 of intravenous CLE
was markedly lower than that of CLA solution administrated orally. CLE exhibited pro-
nounced antibacterial activity and might be a candidate for a new nanocarrier for CLA with
potential advantages over the current commercial formulation.
© 2016 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Clarithromycin (CLA), an erythromycin analogue with a
14-membered ring structure, exhibits important new proper-
ties following substitution of a methoxy group (-OCH3) for
the C6 hydroxy group (-OH) of erythromycin [1]. These struc-
tural modifications allow CLA to perform better than
erythromycin in terms of acid stability, pharmacokinetics,
gastrointestinal adverse effects and antibacterial spectrum.
Clarithromycin is widely used in the treatment of bacterial
infections, and it has been proved to be effective in Mycobac-
terium avium complex (MAC) infections both in vitro and in
vivo [2–4]. Currently, clarithromycin lyophilized powder for
injection contains ingredients like lactobionic acid and sodium
hydroxide, which causes serious irritation at the injection
site. Therefore, the development of an alternative formula-
tion for intravenous injection with less irritation is necessary
[5].
To obtain a less painful and more stable CLA treatment,
various drug delivery systems for CLA have been studied, such
as micelles [5], liposomes [6,7], emulsions [8–10], and
nanoparticles [11]. However, there are still many problems lim-
iting the clinical applications of these formulations, such as
low entrapment efficiency, intolerable pain, a complex manu-
facturing process, poor physiochemical stability during long-
term storage and the very high cost.
Lipid emulsions have been proven to be ideal carriers for
parenteral drug delivery, due to their unique properties such
as being biodegradable, biocompatible, physically stable, with
low toxicity, and being easy to prepare even on a large scale.
In addition, it had been shown that the oil-in-water emul-
sion system can significantly lower the incidence and the
intensity of pain on injection because direct contact of the
drug with body fluids and tissues is prevented by incorporat-
ing the drug into the oil phase or the interfacial layer [12,13].
So, the possibility of reducing irritation by preparing CLA lipid
emulsions has been demonstrated and a number of related
research studies have been launched. Lovell et al. developed
a less painful clarithromycin emulsion with the aid of lipo-
philic counterions, like hexanoic acid and oleic acid, which
improved the drug solubility in the oil phase [8]. However,
the final emulsion was unable to withstand thermal steriliza-
tion which limited its industrial application. Yan et al. and Jie
et al. reported clarithromycin emulsions containing vitamin
E, a phospholipid complex, and tocopherol succinate (TS) re-
spectively [9,10]. The final emulsions remained stable after
undergoing sterilization at 100 °C in a rotating water bath for
30 min. However, too many excipients were used in the for-
mulation, which limited the safety and tolerability of the
preparation. Currently, many studies are being conducted on
ion-pair, which is a suitable chemical approach to increase
the lipophilicity of drugs, making it easier to incorporate drugs
into the lipid matrix [14–16]. According to Brønsted–Lowry acid–
base theory, strong acids and bases tend to form hydrogen-
bonded ion pair (HIP) by proton transfer, especially in solvents
with a low dielectric constant [17].
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In the case of CLA, it is expected that the dimethylamino
group will probably form strong hydrogen bonds like OH. . .N
followed by proton transfer: OH. . .N⇌ O−. . .HN+, with the ex-
cipient carrying the hydroxyl group. Therefore, it is essential
to find an appropriate counter-ion to interact with CLA. In ad-
dition, to effectively localize the drug in the interfacial lecithin-
rich layer, a thin-film dispersed homogenization method was
developed. The resulting lipid emulsion exhibited good physi-
cal stability.
Based on the above factors, a novel parenteral clarithromycin
lipid emulsion (CLE) with cholesteryl hemisuccinate (CHEMS)
was developed and investigated. Considering that CLA has poor
solubility in both oil and water media, efforts were made to
localize the drug in the interfacial film by H-bonding and the
formation of a hydrogen-bonded ion-pair between CLA and
CHEMS. Also, characterization by DSC and FT-IR analysis was
performed to examine a possible interaction between CLA
and CHEMS. Furthermore, a stability test was carried out after
sterilization and freeze–thawing, which proved that the
clarithromycin lipid emulsion was of high quality. Finally, the
antibacterial activity of the drug was assessed both in vitro and
in vivo. The experimental results obtained showed that CLE ex-
hibited good physical stability, thermal stability, and excellent
antibacterial activity, suggesting that it had great prospects for
clinical applications and its production could also be scaled
up without great expense.
2. Materials and methods
2.1. Materials
The following materials were purchased from or provided by
the sources in parentheses: CLA (Zhejiang Huayi Pharma Ltd.
Co., Zhejiang, China), cholesterol (CHO), CHEMS, and PL-100M
(Shanghai Advanced Vehicle Technology Ltd. Co., Shanghai,
China), Lipoid E80, Lipoid S100, medium chain triglyceride (MCT)
and long chain triglyceride (LCT) (Lipoid KG, Ludwigshafen,
Germany), PC-98T (Q.P. Corporation, Tokyo, Japan), potassium
bromide (FTIR grade) and DMSO-d6 (Sigma Aldrich), Poloxamer
188 (Pluronic F68) (BASF AG, Ludwigshafen, Germany), and glyc-
erol (ZheJiang Suichang Glycerol Plant, Zhejiang, China). Double-
distilled water (DDW) was used throughout the study. All other
chemicals and reagents were of analytical or chromato-
graphic grade.
2.2. Degradation of clarithromycin in different oils
Clarithromycin was dissolved in MCT, LCT and an MCT–LCT
mixture (1:1) by agitation in a water bath maintained at
80 °C. Then, the oils containing 0.2% CLA were sealed in
vials and incubated at 80 °C in a thermostatically controlled
water bath. The samples were then withdrawn at intervals of
0, 1, 2, 4, 6, 8, 12, and 24 h and cooled to room temperature
immediately to terminate the reaction. The drug content was
determined by HPLC as illustrated in Section 2.4, and the
percentage CLA degradation was calculated by the changes
in CLA content.
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2.3. Preparation of CLE
The clarithromycin lipid emulsion with a concentration of
5.0 mg/ml was prepared by a thin-film dispersed homogeni-
zation method. CLA, CHEMS and 2.0% (w/v) PL-100M were
dissolved in an appropriate amount of anhydrous ethanol at
60 °C.Then, the mixture was transferred to a round bottom flask
and the organic reagent removed in a rotary evaporator (N-
1001, EYELA, Japan). The aqueous phase containing 2.5% (w/
v) glycerol was adjusted to pH 8.0 with 0.05 mol/l NaOH and
heated at 60 °C. After removal of ethanol, the aqueous phase
was added to the round bottom flask. The system was stirred
at 60 °C until the lecithin had uniformly dispersed, giving the
drug in the aqueous phase. The oil phase (MCT, 15% w/v, pre-
heated at 60 °C) was added slowly to the aqueous phase
containing the drug under high shear mixing (ULTRA TURRAX®
T18 basic, IKA® WORKS, Germany) at 10,000 r/min over 3 min
to prepare the coarse emulsion, and the final volume was ad-
justed to 100 ml with water for injection. The final emulsion
was prepared using a high-pressure homogenizer (pharma-
ceutical ultra-high pressure homogenizer of AH100D, ATS
Engineering Inc., China) operated at 600 bar for 8 cycles with
cooling water circulating around the equipment. The pH of the
final emulsion was adjusted to 8.0 with 1 mol/l NaOH. Finally,
the emulsion was sealed in vials in an atmosphere of nitro-
gen and autoclaved at 121 °C for 10 min. After thermal
sterilization, the emulsion was immediately cooled to 25 °C.
Formulation investigations of CLE were conducted with a single-
factor test. Also, microscopic examination was carried out using
a Motic DMBA450 microscope (MoticChina Group Co. Ltd.,
Beijing, China) to check if there were any particles more than
5 micron in the system.
2.4. Characterization of CLE
The particle size distribution (PSD) and zeta potential of CLE
were measured by photon correlation spectroscopy (PCS) and
electrophoretic light scattering (ELS) respectively, using
a NicompTM 380 Particle Sizing system (Zeta Potential/Particle
Sizer NicompTM 380ZLS, Santa Barbara, California, USA). Samples
were immediately diluted 1:5000 with double distilled water
to obtain an optimum scattering intensity before measure-
ment at 25 °C.
A reverse phase HPLC analytical method was used for the
drug analysis [9]. The method was validated in terms of its se-
lectivity, linearity, accuracy and precision.
The interfacial drug-loading was evaluated using the ul-
tracentrifugation technique. The CLE sample was centrifuged
at 50,000 r/min for 2 h using CS120GXL (Hitachi Koki Co., Ltd.,
Tokyo, Japan). The resulting oil phase and water phase were
collected and their CLA content was assayed by HPLC.The total
amount of CLA in CLE was determined after disrupting the
emulsion with ethanol. The interfacial drug-loading content
(%) was calculated based on the following equation:
Interfacial drug-loading W WW O% % %( ) ( ) − ( )= −1
where WW (%) and WO (%) are the drug contents (%) in the water
phase and the oil phase, respectively.
2.5. Possible interaction between CLA and CHEMS
2.5.1. Preparation of the CLA–CHEMS complex and physical
mixtures
Different molar ratios of CLA and CHEMS were dissolved in an-
hydrous ethanol under gentle stirring at 60 °C for 30 min.Then,
the organic phase was removed under vacuum at 60 °C. The
resulting product was the CLA–CHEMS ion-pair complex.
CLA–CHEMS physical mixtures were prepared by blending
the two ingredients in different molar ratios in a porcelain
mortar for 30 min.
All the powders mentioned above were collected and sealed
in tight glass vials at 4 °C until required for use.
2.5.2. Characterization of CLA–CHEMS complex
Samples (3–5 mg) were sealed in aluminum pans fitted with
perforated lids, using an empty pan as control. All samples were
heated at a rate of 10 °C/min from 25 °C to 250 °C in a nitro-
gen atmosphere (DSC-1, Mettler-Toledo, Switzerland).
FT-IR spectra were recorded on a BRUKER IFS 5S FI-IR system
between 4000 and 400 cm−1 using the KBr disk method.
Samples were dissolved in deuterated dimethyl sulfoxide
(DMSO-d6) and then transferred to NMR tubes for analysis. NMR
spectra were recorded on an Advance Bruker instrument (1H
at 600 MHz). The chemical shifts were relative to the
tetramethylsilane (TMS) signal at 0 ppm for 1H NMR.
2.6. Stability study
2.6.1. Thermal sterilization test
The final emulsion of clarithromycin was prepared according
to Section 2.3.Then, several thermal sterilization methods were
selected and used to optimize the sterilization conditions, in-
cluding (i) in a 100 °C rotating water bath for 30 min; (ii) in a
100 °C rotating water bath for 45 min; (iii) autoclaving at 100 °C
for 45 min; (iv) autoclaving at 115 °C for 30 min; (v) autoclav-
ing at 121 °C for 8 min; and (vi) autoclaving at 121 °C for 10 min.
Different indicators were used to evaluate the stability of the
samples.
2.6.2. Freeze–thaw stability test
CLE samples were frozen in a freezer at −20 °C for 12 h and then
thawed at ambient temperature for another 12 h. The freeze–
thaw cycle was repeated 3 times. The stability of CLE was
evaluated by its physical appearance and PSD after each cycle.
2.7. Microbiology test
2.7.1. Susceptibility test
Minimal inhibitory concentrations (MICs) of CLA, CLA–CHEMS
and CLE were determined by the agar dilution method as pro-
posed by the National Committee for Clinical Laboratory
Standards [18]. Agar plates were prepared by serial twofold di-
lution. The inocula were adjusted to give a final cell density
of approximately 104 CFU/ml, and the determined concentra-
tion of antimicrobial drug ranged from 0.031 to 256 mg/l. CLA
and drug-free lipid emulsions were used as positive and nega-
tive controls, respectively.The MIC values (mg/l) were evaluated
according to the actual CLA concentration in each sample.
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The medium and incubation conditions were as follows:
Mueller-Hinton agar (MHA) with 5% sheep blood for Strepto-
coccus pneumoniae, 35 ± 2 °C, 5%CO2, 20 to 24 h; Haemophilus
test medium (HTM) for Haemophilus influenzae, 35 ± 2 °C, 5%CO2,
20 to 24 h; and Mueller-Hinton agar (MHA) for all other strains
and incubated for 16 to 18 h at 35 ± 2 °C in ambient air.
2.7.2. Mouse model of sepsis
Isolates of Staphylococcus aureus and Streptococcus pneumonia were
obtained from clinical sources. The medium and incubation
conditions for the organisms were the same, as illustrated in
Section 2.7.1. The single bacterial colonies were grown over-
night at 37 °C in appropriate broth and then diluted to the
minimum lethal dose (MLD) with 5% dry yeast. The following
experiments on mice with septicemia caused by the two strains
were conducted separately [19].
Kunming mice of SPF grade weighing 18~22 g were kindly
provided by the Experimental Animal Center of Academy of
Military Medical Sciences. All animal experiments were carried
with the permission of the local animal ethical committee, and
conformed to the Guide for Care and Use of Laboratory Animals.
In this test, mice were randomly divided into eighteen groups
each of ten animals (five males and five females per group) and
fasted overnight prior to the experiment. Mice were infected
intraperitoneally with 0.5 ml of the bacterial suspension. At 1 h
after infection, seven groups of mice each were treated
intragastrically with different doses of CLA, and seven groups
intravenously with CLE. Percentages of animals receiving each
dose surviving to day 7 after infection were recorded, and the
50% effective doses and 95% confidence limits were calcu-
lated by the BLISS method.
3. Results and discussion
3.1. Preparation investigations of the CLE
3.1.1. Investigation of oil phase composition
The composition of the oil phase has a great influence on the
physicochemical stability of lipid emulsions. LCT and MCT have
been mainly used for many years as the oil phase in clinical
applications.
Accordingly, a 15% (w/v) oil phase of LCT and MCT, in the
ratio of 7.5:7.5, was employed to evaluate the effect of the oil
composition on the physicochemical properties of the CLE.The
particle size distribution and physical appearance were chosen
as the main parameters for evaluation, as shown in Table 1.
Referring to the formulation A3, it was obvious that when using
LCT as the oil phase, there were visible oil droplets on the
surface of the CLE. Oil droplets appeared in formulation A2 after
3 months of storage at 25 °C. This could be explained by the
increased interfacial tension in the presence of the continu-
ous phase caused by the relatively longer hydrocarbon chain
of LCT [20], which adversely affected the strength of the oil film,
making it too weak to withstand sterilization or long-term
storage.
Furthermore, the degradation profiles of CLA in different oils
were evaluated at 80 °C, by monitoring the change in CLA con-
centration over 24 h. As shown in Fig. 1, CLA underwent a
marked degradation in LCT over 24 h with a concentration re-
duction of about 20%. However, there was very little drug
degradation in the case of MCT. The reason for the difference
in CLA chemical stability between LCT and MCT was consid-
ered to be the saturation level of the fatty acids, the unsaturated
fatty acids in LCT being more active than the inert saturated
fatty acids in MCT, allowing the release of radicals and per-
oxides at a high temperature [21]. However, the peroxy radical
produced during the oxidization process would accelerate the
peroxidation of CLA while the hydrogen peroxide produced was
liable to be degraded into low molecular weight substances con-
taining carbonyl groups, and then undergo further oxidation
to carboxylic acids leading to the degradation of CLA. There-
fore, the addition of MCT to the oil phase of the CLE would
reduce the degradation of CLA. Compared with LCT, MCT had
a better immune-system profile since it is not involved in pros-
taglandin and leukotriene metabolism [22]. In addition, MCT
Table 1 – The effect of oil phase composition on the characterization of CLE.
Each 100 ml CLE Oil phase (%,w/v) Particle size distribution (nm) Physical appearance
MCT:LCT Before
sterilization
After
sterilization
After sterilization After 3-month
storage at 25 °C
Formulation A1 15:0 200.3 ± 58.3 186.6 ± 69.0 Good Good
Formulation A2 7.5:7.5 206.3 ± 98.2 288.3 ± 77.0 Good Visible oil droplets
Formulation A3 0:15 240.7 ± 77.7 248.4 ± 100.3 Visible oil droplets ND
ND: not determined; Good: appeared to be a homogeneous milky appearance.
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Fig. 1 – The degradation of CLA in different oils at 60 °C
within 24 h.
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could be a source of energy due to rapid hydrolysis and oxi-
dation [23]. Moreover, using MCT as the oil phase could reduce
the viscosity of the system, which would undoubtedly benefit
the large scale production.
3.1.2. Investigation of different kinds of lecithin
It is well known that the emulsification process, which mainly
depends on the emulsifiers used, plays a critical role in the sta-
bility of lipid emulsions. Natural lecithin obtained from animal
(egg yolk) or plant (soybean) sources is commonly used as an
emulsifier in the preparation of lipid emulsions, exhibiting ex-
cellent biocompatibility. Influence of the lecithin type on the
lipid emulsion was investigated using formulations B1–B4 pre-
pared according to Section 2.3 (Table 2).
Natural lecithin contains a variety of components like phos-
phatidic acid (PA), phosphatidylinositol (PI), phosphatidylserine
(PS) and some other ionic components. The content of these
components is usually low but they can increase the heat-
stress and storage stability of the emulsion through increasing
the ζ-potential of the oil droplets [24]. The phosphatidylcho-
line (PC) content (%) of the natural lecithin used in this test
was PC-98T (98.6%) > S100 (96%) > E80 (82.1%) > PL-100M (80.1%).
Formulation B3 and B4 with S100 and PC-98T produced un-
stable lipid emulsions with visible oil droplets appearing after
storage at 60 °C for 5 d, and this result was consistent with the
components in the different types of lecithin illustrated above.
Formulation B2 with E80 showed good physical stability as re-
flected by PSD and its appearance, whereas the pH after
sterilization decreased markedly. Moreover, the content of CLA
in the CLE decreased drastically after a month of storage at
room temperature (data not shown). This could be explained
by the fact that E80 is hydrolyzed in an alkaline and high tem-
perature environment especially in the presence of electrolytes.
Hydrolysis of E80 would produce free fatty acids, which would
then trigger the chemical degradation of CLA, since CLA is very
unstable in acid [1]. Formulation B1 with PL-100M exhibited
good chemical and physical stability during autoclaving and
storage processes. The excellent emulsifying effects could be
attributed to the minor components in PL-100M, including
sphingomyelin, cholesterol, and lysophosphatidylcholine. In ad-
dition, PL-100M is stable in alkaline conditions, which would
prevent CLA from further degradation and ensure the storage
stability of CLE at a final pH of 8.0.
3.1.3. Investigations of membrane stabilizers in the CLE
The choice of membrane stabilizer also plays an important role
in the preparation of a lipid emulsion. A mixture of emulsifi-
ers can form a close-packed complex interfacial film that is
less susceptible to breakdown during sterilization.
Cholesterol (CHO) is a fundamental component of the cell
membrane, and it can stabilize the cell membrane by modi-
fying the mobility and order of the phospholipids. Also,
hydrogen bonds can be formed between CHO and drugs with
an ester group to prevent drug leakage [25,26]. As shown in
Table 3, formulation C1 with a single emulsifier of PL-100M was
unable to form a stable interfacial film and so there was pre-
cipitation after sterilization. Also, no substantial improvement
in the stability of formulation C2 was produced by the addi-
tion of CHO. This phenomenon could be explained by the fact
that the interaction between CLA and CHO was not strong
enough to maintain CLA in the interfacial lecithin layer of the
lipid emulsion. Above all, one prerequisite for localizing the drug
efficiently in the interfacial film is a strong interaction between
the drug and excipient used in the formulation.
Since the dimethylamino group of CLA can interact with
substances containing carboxyl groups, like hexyl acid through
a lipophilic ion-pair [7,8], cholesteryl hemisuccinate (CHEMS),
Table 2 – The effect of types of lecithin on the characterization of CLE.
Each 100 ml
CLE
Lecithin
type
Particle size distribution (nm) △pH
valuea
Physical appearance
Before sterilization After sterilization Before sterilization After sterilization
Formulation B1 PL-100M 200.3 ± 58.3 186.6 ± 69.0 −0.20 Good Good
Formulation B2 E80 210.5 ± 55.6 209.5 ± 66.4 −0.53 Good Good
Formulation B3 S100 328.1 ± 141.1 272.7 ± 131.7 −0.61 Good Visible oil droplets
Formulation B4 PC-98T 233.6 ± 77.3 226.1 ± 72.6 −1.51 Good Visible oil droplets
a The pH value difference between before and after sterilization.
Table 3 – The effect of types of membrane stabilizers on the characterization of CLE.
Each 100 ml CLE Membrane
stabilizers type
Physical appearance
After sterilization After one-month
storage at 25 °C
Formulation C1 None Drug precipitation ND
Formulation C2 CLA:CHO (1:2) Drug precipitation ND
Formulation C3 CLA:CHEMS (2:1) Drug precipitation ND
Formulation C4 CLA:CHEMS (1:1) Good Drug precipitation
Formulation C5 CLA:CHEMS (1:2) Good Good
ND: not determined.
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consisting of succinic acid esterified to the β-hydroxyl group
of CHO, was also investigated in the CLE. The effect of adding
different amounts of CHEMS in the preparation of CLE was
evaluated and the results are shown in Table 3. Addition of
CLA and CHEMS at a molar ratio at 1:2 (formulation C5)
markedly improved the stability of CLE. Also, formulations
C3 and C4 with less CHEMS added exhibited poor stability
during autoclaving or storage, due to breakdown of the inter-
facial film and precipitation of the drug from the phospholipid
bilayer. Based on these results, CHEMS (CLA: CHEMS, M ratio
1:2) was judged to be suitable and essential for the prepara-
tion of CLE.
In addition, Pluronic F68 is commonly used as a co-emulsifier
in lipid emulsions since it can rapidly stabilize the newly created
interface [27]. The effect of F68 addition was also investi-
gated. Lipid emulsions stabilized by F68 (0.2%, w/v), PL-100M
and CHEMS (CLA: CHEMS, M ratio 1:2) displayed almost the
same behavior as the formulation without F68 during a three-
month storage at 25 °C (data not shown), whereas coalescence
and cracking appeared after a six-month storage. Also, it was
found that addition of excess co-emulsifier interfered with the
formation of the interfacial film. Moreover, it has been re-
ported that parenteral administration of F68-based formulations
induce non-IgE-mediated hypersensitivity reactions in some
individuals [28,29]. So, the use of F68 should be limited since
a pliable close-packed interfacial film could already be formed
by PL-100M and CHEMS.
3.2. Verification of interaction between CLA and CHEMS
To confirm the interaction between CLA and CHEMS, DSC and
FT-IR analyses were carried out. In addition, the possible for-
mation mechanism was also considered.
3.2.1. DSC analysis
Fig. 2Ashows the DSC curves of CLA, CHEMS, CLA–CHEMS physi-
cal mixture (PM) and the equivalent molar complex (CP). Pure
CLA and CHEMS samples exhibited sharp endothermic peaks
around 231 °C and 186 °C, which were attributed to their re-
spective melting temperatures.The calorimetric analysis of the
physical mixture and complex in different molar ratios showed
an endothermic signal at about 157 °C, which was not present
in the endothermic peaks of the two starting compounds, in-
dicating the formation of a new chemical entity. The DSC
profiles of PM suggested that CLA and CHEMS could interact
and form a new complex simply by trituration without any
solvent.
3.2.2. FT-IR analysis
In order to further investigate the possible mechanism of the
interaction between CLA and CHEMS, pure CLA, CHEMS and
CLA–CHEMS physical mixture (PM) and complex (CP) at dif-
ferent molar ratios were subjected to FT-IR analysis (Fig. 2B).
The spectrum of CLA showed characteristic absorption
bands of the hydroxyl group, and ketone and lactone car-
bonyl groups of CLA around 3468 cm−1, 1691 cm−1, and 1733 cm−1.
The signal of the lactone carbonyl group of CHEMS was ob-
tained around 1731 cm−1, which overlapped that of CLA and,
also, the absorption peak of the carboxylic acid carbonyl group
at 1706 cm−1 was observed. The IR spectra of the 1:2 CLA and
CHEMS complex showed some differences compared with other
samples and confirmed the formation of a new complex. Signals
around 1635 cm−1 and 1573 cm−1 were attributed to the asym-
metrical stretching vibration of the carboxylic salt bonds and
the bending vibration of an ammonium ion, respectively, which
indicated the occurrence of proton translocation between the
carboxyl and amino groups or, in other words, the formation
of HIP. This interaction would increase the lipophilicity of CLA
and, thus, help the localization of the drug in the phospholipid-
rich phase. Moreover, the broadening of the hydroxyl band and
the disappearance of the ketone band in the spectrum of the
complex compared with its physical mixture indicated the for-
mation of a hydrogen bond between CLA and CHEMS.
Consequently, it was concluded that for CLE, the H-bonding
and hydrogen-bonded ion pair interaction between CLA and
CHEMS (Fig. 3) effectively “locked” CLA in the interfacial film,
thereby reducing the injection pain by decreasing the amount
of free drug in the aqueous phase. Therefore, it is feasible to
increase the CLA stability in the lipid emulsion by H-bonding
and formation of a CLA–CHEMS hydrogen-bonded ion pair
complex. These results confirm the optimal formulation com-
position of CLE.
3.2.3. 1H NMR analysis
The 1H NMR spectra of CLA, CHEMS and CLA–CHEMS complex
(molar ratio 1:2) are shown in Fig. 4. The signal of the proton
from the hydroxyl group of CHEMS (12.27 ppm) was shifted
upfield in the CLA–CHEMS complex (9.32 ppm), which
indicated the formation of N-H. These data suggested coordi-
nate bond formation between CLA and CHEMS, which offered
further evidence for the formation of HIP after FT-IR
spectroscopy.
3.2.4. Possible formation mechanism of H-bonding and HIP
CLA–CHEMS complex (HHIPC)
Different from the other studies, the CLA–CHEMS ion pair
complex was prepared in anhydrous ethanol, which is a solvent
with low toxicity and a high dielectric constant. It is well known
that solvents with a low dielectric constant can contribute to
the formation of ion-pair, since in solvents with a high dielec-
tric constant, the interionic attraction between ion pair might
be weakened due to the formation of hydrogen bonds with
solvent molecules. However, results showed that the interac-
tion between CLA and CHEMS was strong enough to form a
hydrogen-bonded ion pair and keep it stable in a solvent with
a high dielectric constant. Ion pairing is a chemical approach
to make ionized drugs and counter ions interact with each other
in solvents to form a distinct chemical entity through Coulomb
attraction.The electrostatic force is described by Coulomb’s law
as follows:
F
q q
r
=
1 2
2ε
where F is the force of attraction, q1 and q2 are the magni-
tudes of the electrical charges, ε is the dielectric constant of
the medium, and r is the distance between the ions. It could
be speculated that with regard to the CLA–CHEMS ion pair
complex, q1, q2, and ε were constant, while the distance between
the cation and anion was variable. It might be that in the
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Fig. 2 – DSC thermograms (A) of CLA, CHEMS, different molar radios of physical mixture (PM) and complex (CP). FI-IR spectra
(B) of CLA, CHEMS, different molar radios of physical mixture (PM) and complex (CP).
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process of ion pair complex preparation, the attraction force
increased when the distance between CLA and CHEMS was
reduced. As shown in Fig. 5A, when CLA and CHEMS were dis-
solved in anhydrous ethanol, both ions underwent complete
solvation. Then, with the evaporation of the solvent, CLA and
CHEMS became closer and shared about one molecule of
solvent. Finally, CLA and CHEMS interacted with each other to
form an HHIPC. The whole preparation process of CLE is de-
scribed in Fig. 5B. Similarly, in the case of CLE, CLA, CHEMS
and PL-100M were dissolved in anhydrous ethanol, and an
HHIPC with improved lipophilicity was possibly formed and
intercalated between the acyl hydrocarbon chains of the phos-
pholipids after removal of the solvent (Fig. 5A). When adding
oil to the drug-containing water phase, the lipid bilayer is con-
verted to a monolayer which stabilizes the formed oil-in-
water (o/w) structure. After high pressure homogenization and
thermal sterilization, a re-emulsifying and re-constituting
lipid emulsion is obtained. No globules in the micron range
were found in this system following microscopic observa-
tions in more than 20 fields, indicating that the prepared CLE
was safe for intravenous administration. Consequently, CHEMS
(CLA: CHEMS, M ratio 1:2) was suitable for the preparation of
a stable CLE.
To verify whether the CLA–CHEMS ion-pair was located in
the lecithin-rich interfacial film, ultracentrifugation was used
to separate different phases in the CLE. By analyzing the CLA
content (%) in the oil phase and water phase, the CLA content
(%) in the interfacial film was obtained by subtracting them
from the total CLA content. Due to the formation of HHIPC,
the CLA contents in the oil phase or water phase were less than
2% and about 10%, respectively, indicating that approxi-
mately 88% CLA was located in the interfacial layer.
Simultaneously, a small quantity of CLA with improved
lipophilicity could also distribute in the oil phase during
the process of high speed shearing and high pressure
homogenization.
3.3. Stability test
3.3.1. Thermal sterilization test
The physical stability of emulsions is the primary concern
during terminal autoclaving, because it is a prerequisite for de-
veloping stable formulations [30]. In general, the methods of
sterilization are mainly dependent on the nature and excipi-
ents of the preparation, and for lipid emulsions, the preferred
and reliable sterilization process is steam sterilization. As for
thermal sterilization, temperature and time play important roles
Fig. 3 – The schematic representation of H-bonding and HIP CLA–CHEMS complex formation.
14 12 10 8 6 4 2 0 -2
f1 (ppm)
CLA
CHEMS
CP 1:2
Fig. 4 – The 1H NMR spectra of CLA, CHEMS and complex
(CP, molar ratio 1:2).
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in the destruction of microorganisms by heat. Also, it has been
reported that thermal sterilization might cause irreversible re-
distribution of emulsifier compounds and more rapid Brownian
motion, which affects the physical and chemical stability of
lipid emulsions [31]. So, the PSD, polydispersity index (PI), drug
loading content, pH value, and physical appearance of lipid
emulsions before and after sterilization were chosen as the
main parameters for evaluation.
The influence of the sterilization methods on the proper-
ties of the lipid emulsion is presented in Table 4. From these
results it can be clearly seen that sterilization in a 100 °C ro-
tating water bath for 30 min and 45 min, and autoclaving at
115 °C for 30 min, led to a markedly wider PI compared with
the pristine lipid emulsions. The dramatic changes in par-
ticle size indicated droplet aggregation during these sterilization
processes. Autoclaving at 115 °C for 30 min even led to a marked
reduction in drug content. It should be noted that heating would
also induce the degradation of phospholipids, producing free
fatty acids or lysophosphatides, which might cause toxicity and
reduce the pH. As shown in Table 4, there was a decrease in
pH in emulsions sterilized by methods ii–iv. Since CLA is liable
to degrade in an acidic environment, it is necessary to keep
the pH within an acceptable range. Also, these preparations
displayed poor stability with visible oil droplets appearing after
Fig. 5 – Possible formation mechanism (A) of H-bonding and HIP CLA–CHEMS complex. The whole preparation process (B) of
clarithromycin lipid emulsion (CLE). (1) Possible structure of CLA, CHEMS and phospholipid after evaporation or in water
phase. (2) Possible structure of CLE. (3) TEM image of CLE. (4) Microscopic observations of CLE.
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10 d of storage at 25 °C. However, the formulation exhibited good
stability when autoclaved at 121 °C for 8 min and 10 min, in-
dicating the superiority of autoclaving at 121 °C over other
sterilization methods. It is well known that a higher steriliza-
tion temperature and a shorter sterilization time are preferable
when the sterilizing effects are similar on account of the lower
activation energy of drug degradation. To ensure a better ster-
ilization effect, autoclaving at 121 °C for 10 min was selected
as the optical sterilization method.
3.3.2. Freeze–thaw stability test
The effect of environmental stresses, such as freeze–thawing
treatment, was studied. For lipid emulsions, crystallization of
the oil or aqueous phase and droplet coalescence might occur
during freezing and thawing [32]. The PSD and physical ap-
pearance were recorded after each freeze–thawing cycle to
characterize the stability of the CLE. No marked change in par-
ticle size was observed after the process of freeze–thawing
(Fig. 6), indicating the good freeze–thawing stability of the CLE,
which was ascribed to the thick interfacial membrane formed
by PL-100M and CHEMS that was able to protect the lipid emul-
sion droplets from coalescence under extreme conditions.
Hence, a formulation of 1:2 CLA and CHEMS with 2.0% PL-
10M seems to be an attractive formulation with satisfactory
properties.
3.4. Microbiology testing
3.4.1. Susceptibility test
The in vitro antibacterial activity of the CLE and HHIPC was
tested by the MIC method, and the MICs of the CLE and HHIPC
were compared with that of the parent drug and drug-free lipid
emulsions against Staphylococcus aureus, Streptococcus pneumoniae,
Haemophilus influenzae, and Pseudomonas aeruginosa. As ex-
pected, blank lipid emulsions exhibited no antibacterial activity
against all the tested strains. The results showed that the MICs
of the formulations tested were similiar (Table 5), which sug-
gested that HHIPC and CLE exhibited similiar activity to the
parent drug against different bacterial strains, either sensi-
tive or resistant to CLA, while HHIPC appeared to be more active
than CLA against Haemophilus influenzae. From these results it
could be confirmed that the formation of HHIPC and the prepa-
ration of the CLE did not influence drug permeability and
transport through biological membranes [33]. Based on these
results, further research on in vivo antibacterial activity was
conducted.
3.4.2. Mouse model of sepsis
The results of CLA oral administration and CLE intravenous
administration in sepsis studies are shown in Fig. 7A and Fig. 7B.
For Staphylococcus aureus, the 50% effective dose (ED50) of CLE
was 1.929 mg/kg (95% confidence interval, 1.310~2.843 mg/
kg), which was much more efficacious than CLA with an ED50
of 12.941 mg/kg (95% confidence interval, 8.296~20.187 mg/
kg). Similar observations were obtained in the sepsis mouse
model of infection due to Streptococcus pneumoniae; the
ED50 of CLE was 0.678 mg/kg (95% confidence interval,
0.442~1.040 mg/kg), which was superior to that of CLA with
an ED50 of 2.406 mg/kg (95% confidence interval, 1.709~3.387 mg/
kg). So, it appeared that for Streptococcus pneumoniae, CLE was
3 to 4 times more active in vivo than CLA, and for Staphylococ-
cus aureus, CLE administrated intravenously was at least
six-fold more potent than CLA given orally. The difference
between CLA and CLE was determined by the BLISS method
(P < 0.05).
Table 4 – The effect of different sterilization methods on the characterization of CLE.
Sterilization method pH PSD (nm) PI Drug
content (%)
Physical appearance
After
sterilization
After 10 days of
storage at 25 °C
Before sterilization 8.20 206.2 ± 54.6 0.070 100.0 Good Good
Method i 7.91 210.0 ± 72.9 0.120 99.4 Good Good
Method ii 7.82 197.9 ± 79.4 0.161 98.5 Good Visible oil droplets
Method iii 7.83 204.6 ± 44.4 0.047 98.7 Good Visible oil droplets
Method iv 7.83 207.7 ± 67.1 0.104 97.2 Good Visible oil droplets
Method v 7.94 208.5 ± 36.3 0.030 99.5 Good Good
Method vi 7.90 202.3 ± 54.2 0.072 99.3 Good Good
Sterilization methods (i) 100 °C rotating water bath for 30 min; (ii) 100 °C rotating water bath for 45 min; (iii) autoclave at 100 °C for 45 min; (iv)
autoclave at 115 °C for 30 min; (v) autoclave at 121 °C for 8 min; and (vi) autoclave at 121 °C for 10 min.
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Fig. 6 – Particle size with INT-WT and VOL-WT after each
freeze–thawing cycle. INT-WT: intensity weighting; VOL-
WT: volume weighting.
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Sepsis is a whole-body inflammatory response commonly
triggered by bacterial infection. It has also been reported that
CLA exhibits a range of immunomodulatory and anti-
inflammatory properties [34].The efficacy of CLA in sepsis might
be attributed to its ability to inhibit the formation of a bacte-
rial biofilm on the airways, as well as the production of various
inflammatory mediators by alveolar macrophages and blood
monocytes [35]. Several studies have reported that following
intravenous administration, lipid emulsions are readily taken
by mononuclear phagocyte systems, and then preferentially
distributed within inflammatory areas or other peripheral
tissues [36]. After infecting different groups of mice with bac-
terial suspensions, mononuclear phagocyte cells showed a
tropism to the vaccination site.Therefore, CLE carried by mono-
nuclear phagocyte cells could exert an effective therapeutic
potency. This could also explain why CLA administered orally
displayed poor antibacterial activity on account of low
bioavailability. From these results it can be concluded that the
administration route is important for the efficacy of CLA in the
treatment of sepsis. The experiments conducted in our study
here have successfully encapsulated antibiotics into lipid emul-
sion delivery system by formation of H-bonding and HIP CLA–
CHEMS complexes.
4. Conclusions
The present study was carried out to investigate the formu-
lation and in vivo antibacterial activity of an intravenous
clarithromycin lipid emulsion (CLE) prepared by a thin-film dis-
persed homogenization method. An excess of CHEMS (CLA:
CHEMS, M ratio 1:2) helped the formation of H-bonding and
an HIP CLA–CHEMS complex and improved the lipophilicity of
CLA. This allowed CLA to be localized in the interfacial film
with less free drug partitioning in an aqueous milieu, thus im-
proving patient compliance by reducing the irritation of CLA
following injection. Antibacterial testing showed that the CLE
exhibited marked antibacterial activity in vivo, which con-
firms that CLA offers great promise in clinical applications.
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Table 5 – In vitro antibacterial activities (MIC, mg/l).
Bacterial strain Quality CLAa HHIPC CLE Blank lipid emulsiona
ATCC29213
Staphylococcus
Quality control 0.25 0.25 0.25 >256
11E213
Staphylococcus
CLA-susceptible 0.125 0.125 0.125 >256
11O192
Staphylococcus
CLA-susceptible 0.125 0.125 0.125 >256
11P377
Staphylococcus
CLA-resistant 8 32 8 >256
11X298
Staphylococcus
CLA-resistant 8 32 8 >256
ATCC49619
Streptococcus pneumoniae
Quality control 0.062 0.125 0.062 >256
12–143
Streptococcus pneumoniae
CLA-susceptible 0.062 0.031 0.062 >256
12–356
Streptococcus pneumoniae
CLA-susceptible 0.062 0.031 0.062 >256
11B398
Streptococcus pneumoniae
CLA-resistant 8 8 32 >256
11J125
Streptococcus pneumoniae
CLA-resistant 2 2 2 >256
ATCC49247
Haemophilus influenzae
Quality control 8 8 8 >256
11J232
Haemophilus influenzae
CLA-susceptible 2 2 1 >256
11P052
Haemophilus influenzae
CLA-susceptible 2 2 2 >256
11R005
Haemophilus influenzae
CLA-resistant 32 32 32 >256
11R010
Haemophilus influenzae
CLA-resistant 64 64 64 >256
13O327
Pseudomonas aeruginosa
– 128 128 256 >256
13O326
Pseudomonas aeruginosa
– 128 128 256 >256
MIC: values were counted based on the actual concentration of CLA in each sample.
a The antibacterial activity of CLA and blank emulsion was evaluated for comparison.
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